Century Therapeutics (IPSC) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Century Therapeutics (IPSC) has outperformed Sol-Gel Technologies (SLGL) over the past year, gaining 150.0% versus a gain of 78.9%. Over five years, SLGL leads with a -24.6% price change compared with -92.4% for IPSC. Century Therapeutics is the larger company by market cap ($266.2 million vs $235.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPSC | SLGL |
|---|---|---|
| Share price | $1.47 | $71.77 |
| Market cap | $266.18M | $234.97M |
| 1-day change | +0.68% | +2.03% |
| YTD return | +46.73% | +66.92% |
| 1-year return | +150.00% | +78.89% |
| 5-year return | -92.44% | -24.57% |
| EPS (TTM) | $-0.93 | $-5.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.04 | $97.97 |
| 52-week low | $0.435 | $28.81 |
| Distance from 52-week high | -51.64% | -26.74% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +223.13% | +112.48% |
| Average volume | 653.18K | 55.55K |
| Shares outstanding | 181.08M | 3.27M |
| Employees | 78 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed SLGL by 71.1 percentage points over the past year.
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
IPSC vs SLGL FAQ
Which is bigger, Century Therapeutics or Sol-Gel Technologies?
Century Therapeutics (IPSC) is larger, with a market capitalization of $266.18M compared with $234.97M for Sol-Gel Technologies (SLGL).
Which stock has performed better over the past year, IPSC or SLGL?
IPSC returned +150.00% over the past 12 months, compared with +78.89% for SLGL (price return, excluding dividends). Past performance does not predict future results.
Are Century Therapeutics and Sol-Gel Technologies in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Century Therapeutics and Biotechnology: Pharmaceutical Preparations for Sol-Gel Technologies.